Enorama Pharma AB (publ) (STO:ERMA)
Sweden · Delayed Price · Currency is SEK 0.7060
+0.0060 (0.86%)
Sep 4, 2026, 9:22 AM CET
Enorama Pharma AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3.26 | 2.74 | 15.77 | 1.36 | 6.85 | 11.04 | |
Revenue Growth | -71.23% | -82.63% | 1061.12% | -80.17% | -37.96% | 414.26% |
Cost of Revenue | 6.3 | 17.78 | 12.07 | 5.26 | 7.46 | 8.9 |
Gross Profit | -3.04 | -15.04 | 3.7 | -3.9 | -0.62 | 2.13 |
Selling, General & Admin | 49.21 | 46.61 | 31.13 | 34.39 | 37.83 | 29.99 |
Other Operating Expenses | 0.1 | -0 | -0.24 | -0.01 | -0.02 | -1.91 |
Operating Expenses | 49.66 | 47.08 | 34.21 | 37.92 | 41.35 | 29.46 |
Operating Income | -52.7 | -62.12 | -30.5 | -41.82 | -41.97 | -27.33 |
Interest Expense | - | -1.17 | -0.43 | -0.88 | -1.27 | -0.8 |
Interest & Investment Income | 4.89 | 0.02 | 0.14 | 0.08 | - | - |
Currency Exchange Gain (Loss) | -11.87 | -11.87 | 4.08 | -1.99 | 0.96 | 0.19 |
Other Non Operating Income (Expenses) | 0 | 0 | - | - | - | 0.2 |
EBT Excluding Unusual Items | -59.68 | -75.14 | -26.71 | -44.61 | -42.28 | -27.74 |
Asset Writedown | - | - | -17.1 | - | - | - |
Pretax Income | -59.68 | -75.14 | -43.81 | -44.61 | -42.03 | -27.74 |
Net Income | -59.68 | -75.14 | -43.81 | -44.61 | -42.03 | -27.74 |
Net Income to Common | -59.68 | -75.14 | -43.81 | -44.61 | -42.03 | -27.74 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | - | 69 | 53 | 28 | 8 | 6 |
Shares Outstanding (Diluted) | - | 69 | 53 | 28 | 8 | 6 |
Shares Change | - | 30.99% | 91.50% | 253.96% | 26.23% | 11.44% |
EPS (Basic) | - | -1.08 | -0.83 | -1.61 | -5.37 | -4.48 |
EPS (Diluted) | - | -1.08 | -0.83 | -1.61 | -5.37 | -4.48 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -53.05 | -59.26 | -35.7 | -41.35 | -32.96 | -30.22 |
Free Cash Flow Per Share | - | -0.85 | -0.67 | -1.49 | -4.21 | -4.88 |
Gross Margin | -93.49% | - | 23.48% | -287.26% | -9.00% | 19.34% |
Operating Margin | -1619.17% | -2267.91% | -193.44% | -3079.82% | -612.90% | -247.63% |
Profit Margin | -1833.52% | -2743.30% | -277.82% | -3285.20% | -613.85% | -251.38% |
Free Cash Flow Margin | -1629.80% | -2163.60% | -226.42% | -3044.85% | -481.35% | -273.87% |
EBITDA | -52.68 | -61.99 | -30.06 | -41.15 | -41.3 | -26.67 |
EBITDA Margin | - | - | -190.63% | - | - | -241.62% |
D&A For EBITDA | 0.02 | 0.13 | 0.44 | 0.68 | 0.67 | 0.66 |
EBIT | -52.7 | -62.12 | -30.5 | -41.82 | -41.97 | -27.33 |
EBIT Margin | - | - | -193.44% | - | - | -247.63% |
Revenue as Reported | 1.77 | -6.74 | 27.61 | 1.12 | 9.44 | 12.95 |